High Blood Pressure & Cardiovascular Prevention

, Volume 23, Issue 3, pp 203–208 | Cite as

Hyperaldosteronism: How to Discriminate Among Different Disease Forms?

  • Valentina Crudo
  • Silvia Monticone
  • Jacopo Burrello
  • Fabrizio Buffolo
  • Martina Tetti
  • Franco Veglio
  • Paolo Mulatero
Review Article


Primary aldosteronism (PA), characterized by the inappropriate and abnormal adrenal secretion of aldosterone, is the most common cause of secondary hypertension. PA has been shown to increase cardiovasular and cerebrovascular risks in comparison with essential hypertension. PA is a multi-faceted disease, which comprises unilateral forms, benefitting from surgical treatment, and bilateral forms, which are the best managed medically. PA is more frequently sporadic, but in some cases, it displays a familial transmission pattern. For these reasons, it is important to diagnose PA early on and correctly distinguish and manage its different forms. In this review, we analyze the different forms of PA, with attention on the diagnostic pathway and the genetics of the disease.


Primary aldosteronism Aldosterone producing adenoma Adrenal vein sampling Secondary hypertension 


  1. 1.
    Mosso L, Carvajal C, González A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella C. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161–5.CrossRefPubMedGoogle Scholar
  2. 2.
    Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Savard S, Amar L, Plouin PF, Steichen O. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013;62:331–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab. 2013;98:4826–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF, Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93:3266–81.Google Scholar
  6. 6.
    Dekkers T, ter Meer M, Lenders JW, Hermus AR, Schultze Kool L, Langenhuijsen JF, Nishimoto K, Ogishima T, Mukai K, Azizan EAB, Tops B, Deinum J, Küsters B. Adrenal nodularity and somatic mutations in primary aldosteronism: One node is the culprit? J Clin Endocrinol Metab. 2014;99:E1341–51.Google Scholar
  7. 7.
    Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol Cell Endocrinol. 2015;411:146–54.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Monticone S, Viola A, Tizzani D, Crudo V, Burrello J, Galmozzi M, Veglio F, Mulatero P. Primary aldosteronism: who should be screened? Horm Metab Res. 2012;44:163–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Burrello J, Monticone S, Buffolo F, Lucchiari M, Tetti M, Rabbia F, Mengozzi G, Williams TA, Veglio F, Mulatero P. Diagnostic accuracy of aldosterone and renin measurement by chemiluminescent immunoassay and radioimmunoassay in primary aldosteronism. J Hypertens 2016;34:920–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Manolopoulou J, Fischer E, Dietz A, Diederich S, Holmes D, Junnila R, Grimminger P, Reincke M, Morganti A, Bidlingmaier M. Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. J Hypertens. 2015;33:2500–11.CrossRefPubMedGoogle Scholar
  11. 11.
    Mulatero P, Monticone S, Bertello C, Mengozzi G, Tizzani D, Iannaccone A, Veglio F. Confirmatory tests in the diagnosis of primary aldosteronism. Horm Metab Res. 2010;42:406–10.CrossRefPubMedGoogle Scholar
  12. 12.
    Nishikawa T, Omura M, Satoh F, Shibata H, Takahashi K, Tamura N, Tanabe A. Guidelines for the diagnosis and treatment of primary aldosteronism-the japan endocrine society 2009. Endocr J. 2011;58:711–21.CrossRefPubMedGoogle Scholar
  13. 13.
    Patel SM, Lingam RK, Beaconsfield TI, Tran TL, Brown B. Role of radiology in the management of primary aldosteronism. Radiographics. 2007;27:1145–57.CrossRefPubMedGoogle Scholar
  14. 14.
    Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, Azizan EAB, Aigbirhio F, Gurnell M, Brown MJ. Evaluation of the sensitivity and specificity of (11)c-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by conn’s adenomas. J Clin Endocrinol Metab. 2012;97:100–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Abe T, Naruse M, Young WF Jr, Kobashi N, Doi Y, Izawa A, Akama K, Okumura Y, Ikenaga M, Kimura H, Saji H, Mukai K, Matsumoto H. A novel CYP11B2-specific imaging agent for detection of unilateral subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2016;101:1008–15.CrossRefPubMedGoogle Scholar
  16. 16.
    Satoh F, Morimoto R, Ono Y, Iwakura Y, Omata K, Kudo M, Takase K, Seiji K, Sasamoto H, Honma S, Okuyama M, Yamashita K, Gomez-Sanchez CE, Rainey WE, Arai Y, Sasano H, Nakamura Y, Ito S. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension. 2015;65:1096–102.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, Mengozzi G, Rabbia F, Terzolo M, Gomez-Sanchez EP, Gomez-Sanchez CE, Veglio F. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab. 2012;97:881–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Williams TA, Peitzsch M, Dietz AS, Dekkers T, Bidlingmaier M, Riester A, Treitl M, Rhayem Y, Beuschlein F, Lenders JWM, Deinum J, Eisenhofer G, Reincke M. Genotype-Specific steroid profiles associated with aldosterone-producing adenomas. Hypertension. 2016;67:139–45.CrossRefPubMedGoogle Scholar
  19. 19.
    Eisenhofer G, Dekkers T, Peitzsch M, Dietz AS, Bidlingmaier M, Treitl M, Williams TA, Bornstein SR, Haase M, Rump LC, Willenberg HS, Beuschlein F, Deinum J, Lenders JW, Reincke M. Mass spectrometry-based adrenal and peripheral venous steroid profiling for subtyping primary aldosteronism. Clin Chem. 2016;62:514–24.CrossRefPubMedGoogle Scholar
  20. 20.
    Kempers MJ, Lenders JW, van Outheusden L, van der Wilt GJ, Schultze Kool LJ, Hermus AR, Deinum J. Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med. 2009;151:329–37.Google Scholar
  21. 21.
    Blake MA, Cronin CG, Boland GW. Adrenal imaging. AJR Am J Roentgenol. 2010;194:1450–60.CrossRefPubMedGoogle Scholar
  22. 22.
    Monticone S, Viola A, Rossato D, Veglio F, Reincke M, Gomez-Sanchez CE, Mulatero P. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol. 2015;3:296–303.CrossRefPubMedGoogle Scholar
  23. 23.
    Monticone S, Satoh F, Giacchetti G, Viola A, Morimoto R, Kudo M, Ikawura Y, Ono Y, Turchi F, Paci E, Veglio F, Boscaro M, Rainey WE, Ito S, Mulatero P. Effect of adrenocorticotropic hormone stimulation during adrenal vein sampling in primary aldosteronism. Hypertension. 2012;59:840–6.CrossRefPubMedGoogle Scholar
  24. 24.
    Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66:607–18.CrossRefGoogle Scholar
  25. 25.
    Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics. 2005;25(Suppl 1):S143–58.CrossRefPubMedGoogle Scholar
  26. 26.
    Burrello J, Monticone S, Tetti M, Rossato D, Versace K, Castellano I, Williams TA, Veglio F, Mulatero P. Subtype diagnosis of primary aldosteronism: approach to different clinical scenarios. Horm Metab Res. 2015;47:959–66.CrossRefPubMedGoogle Scholar
  27. 27.
    Monticone S, Satoh F, Viola A, Fischer E, Vonend O, Bernini G, Lucatello B, Quinkler M, Ronconi V, Morimoto R, Kudo M, Degenhart C, Gao X, Carrara D, Willenberg HS, Rossato D, Mengozzi G, Riester A, Paci E, Iwakura Y, Burrello J, Maccario M, Giacchetti G, Veglio F, Ito S, Reincke M, Mulatero P. Aldosterone suppression on contralateral adrenal during adrenal vein sampling does not predict blood pressure response after adrenalectomy. J Clin Endocrinol Metab. 2014;99:4158–66.CrossRefPubMedGoogle Scholar
  28. 28.
    Rossi GP, Barisa M, Allolio B, Auchus RJ, Amar L, Cohen D, Degenhart C, Deinum J, Fischer E, Gordon R, Kickuth R, Kline G, Lacroix A, Magill S, Miotto D, Naruse M, Nishikawa T, Omura M, Pimenta E, Plouin PF, Quinkler M, Reincke M, Rossi E, Rump LC, Satoh F, Schultze Kool L, Seccia TM, Stowasser M, Tanabe A, Trerotola S, Vonend O, Widimsky J, Wu KD, Wu VC, Pessina AC. The adrenal vein sampling international study (AVIS) for identifying the major subtypes of primary aldosteronism. J Clin Endocrinol Metab. 2012;97:1606–14.Google Scholar
  29. 29.
    Monticone S, Satoh F, Dietz AS, Goupil R, Lang K, Pizzolo F, Gordon RD, Morimoto R, Reincke M, Stowasser M, Mulatero P. Clinical management and outcomes of adrenal hemorrhage following adrenal vein sampling in primary aldosteronism. Hypertension. 2016;67:146–52.CrossRefPubMedGoogle Scholar
  30. 30.
    Stowasser M, Pimenta E, Gordon RD. Familial or genetic primary aldosteronism and gordon syndrome. Endocrinol Metab Clin N Am. 2011;40:343–68, viii.Google Scholar
  31. 31.
    Mulatero P, Tizzani D, Viola A, Bertello C, Monticone S, Mengozzi G, Schiavone D, Williams TA, Einaudi S, La Grotta A, Rabbia F, Veglio F. Prevalence and characteristics of familial hyperaldosteronism: the PATOGEN study (primary aldosteronism in torino-genetic forms). Hypertension. 2011;58:797–803.CrossRefPubMedGoogle Scholar
  32. 32.
    Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J. 1966;95:1109–19.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262–5.CrossRefPubMedGoogle Scholar
  34. 34.
    Mulatero P, Monticone S, Rainey WE, Veglio F, Williams TA. Role of KCNJ5 in familial and sporadic primary aldosteronism. Nat Rev Endocrinol. 2013;9:104–12.CrossRefPubMedGoogle Scholar
  35. 35.
    Carss KJ, Stowasser M, Gordon RD, O’Shaughnessy KM. Further study of chromosome 7p22 to identify the molecular basis of familial hyperaldosteronism type II. J Hum Hypertens. 2011;25:560–4.CrossRefPubMedGoogle Scholar
  36. 36.
    Sukor N, Mulatero P, Gordon RD, So A, Duffy D, Bertello C, Kelemen L, Jeske Y, Veglio F, Stowasser M. Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in italian as well as australian and south american families. J Hypertens. 2008;26:1577–82.CrossRefPubMedGoogle Scholar
  37. 37.
    Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, Ji W, Cho Y, Patel A, Men CJ, Lolis E, Wisgerhof MV, Gellder DS, Mane S, Hellman P, Westin G, Åkerström G, Wang W, Carling T, Lifton RP. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011;331:768–72.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Williams TA, Monticone S, Crudo V, Warth R, Veglio F, Mulatero P. Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. Hypertension. 2012;59:833–9.CrossRefPubMedGoogle Scholar
  39. 39.
    Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, Sterner C, Warth R, Mulatero P, Rainey WE. A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J Clin Endocrinol Metab. 2013;98:E1861–5.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Monticone S, Bandulik S, Stindl J, Zilbermint M, Dedov I, Mulatero P, Allgaeuer M, Lee CCR, Stratakis CA, Williams TA. A case of severe hyperaldosteronism caused by a de novo mutation affecting a critical salt bridge kir3.4 residue. J Clin Endocrinol Metab. 2014;100:E114–8.Google Scholar
  41. 41.
    Scholl UI, Goh G, Stölting G, de Oliveira RC, Choi M, Overton JD, Fonseca AL, Korah R, Starker LF, Kunstman JW. Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet. 2013;45:1050–4.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Monticone S, Else T, Mulatero P, Williams TA, Rainey WE. Understanding primary aldosteronism: Impact of next generation sequencing and expression profiling. Mol Cell Endocrinol. 2015;399:311–20.CrossRefPubMedGoogle Scholar
  43. 43.
    Scholl UI, Stölting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, Prasad ML, Goh G, Carling T, Juhlin CC, Quack I, Rump LC, Thiel A, Lande M, Frazier BG, Rasoulpour M, Bowlin DL, Sethna CB, Trachtman H, Fahlke C, Lifton RP. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife. 2015;4:e06315.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Korah HE, Scholl UI. An update on familial hyperaldosteronism. Horm Metab Res. 2015;47:941–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Williams TA, Lenders JW, Burrello J, Beuschlein F, Reincke M. KCNJ5 mutations: sex, salt and selection. Horm Metab Res. 2015;47:953–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet. 2013;45:440–4.CrossRefPubMedGoogle Scholar
  47. 47.
    Åkerström T, Maharjan R, Sven Willenberg H, Cupisti K, Ip J, Moser A, Stålberg P, Robinson B, Iwen KA, Dralle H, Walz MK, Lehnert H, Sidhu S, Gomez-Sanchez CE, Hellman P, Björklund P. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci Rep. 2016;6:19546.Google Scholar
  48. 48.
    Murthy M, Xu S, Massimo G, Wolley M, Gordon RD, Stowasser M, O’Shaughnessy KM. Role for germline mutations and a rare coding single nucleotide polymorphism within the KCNJ5 potassium channel in a large cohort of sporadic cases of primary aldosteronism. Hypertension. 2014;63:783–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Assié G, Libé R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, Barreau O, Lefèvre L, Sibony M, Guignat L. ARMC5 mutations in macronodular adrenal hyperplasia with cushing’s syndrome. N Engl J Med. 2013;369:2105–14.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Zilbermint M, Xekouki P, Faucz FR, Berthon A, Gkourogianni A, Schernthaner-Reiter MH, Batsis M, Sinaii N, Quezado MM, Merino M, Hodes A, Abraham SB, Libé R, Assié G, Espiard S, Drougat L, Ragazzon B, Davis A, Gebreab SY, Neff R, Kebebew E, Bertherat J, Lodish MB, Stratakis CA. Primary aldosteronism and ARMC5 variants. J Clin Endocrinol Metab. 2015;100:E900–9.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Mulatero P, Schiavi F, Williams TA, Monticone S, Barbon G, Opocher G, Fallo F. ARMC5 mutation analysis in patients with primary aldosteronism and bilateral adrenal lesions. J Hum Hypertens. 2015. doi:10.1038/jhh.2015.98.PubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Valentina Crudo
    • 1
  • Silvia Monticone
    • 1
  • Jacopo Burrello
    • 1
  • Fabrizio Buffolo
    • 1
  • Martina Tetti
    • 1
  • Franco Veglio
    • 1
  • Paolo Mulatero
    • 1
  1. 1.Division of Internal Medicine and Hypertension, Department of Medical SciencesUniversity of TorinoTurinItaly

Personalised recommendations